GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Navidea Biopharmaceuticals Inc (OTCPK:NAVB) » Definitions » Days Sales Outstanding
中文

Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Days Sales Outstanding : 0.00 (As of Sep. 2023)


View and export this data going back to 1992. Start your Free Trial

What is Navidea Biopharmaceuticals Days Sales Outstanding?

Navidea Biopharmaceuticals's average Accounts Receivable for the three months ended in Sep. 2023 was $0.04 Mil. Navidea Biopharmaceuticals's Revenue for the three months ended in Sep. 2023 was $0.00 Mil.

The historical rank and industry rank for Navidea Biopharmaceuticals's Days Sales Outstanding or its related term are showing as below:

NAVB' s Days Sales Outstanding Range Over the Past 10 Years
Min: 13.56   Med: 171.6   Max: 19199
Current: 19199

During the past 13 years, Navidea Biopharmaceuticals's highest Days Sales Outstanding was 19199.00. The lowest was 13.56. And the median was 171.60.

NAVB's Days Sales Outstanding is ranked worse than
99.89% of 888 companies
in the Biotechnology industry
Industry Median: 72.105 vs NAVB: 19199.00

Navidea Biopharmaceuticals's Days Sales Outstanding declined from Sep. 2022 (1,055.08) to Sep. 2023 (0.00).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

Navidea Biopharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Navidea Biopharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navidea Biopharmaceuticals Days Sales Outstanding Chart

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Days Sales Outstanding
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.56 162.22 180.97 238.04 24.33

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,055.08 7,117.50 - - -

Competitive Comparison of Navidea Biopharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, Navidea Biopharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Navidea Biopharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Navidea Biopharmaceuticals's Days Sales Outstanding falls into.


Navidea Biopharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Navidea Biopharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2022 is calculated as

Days Sales Outstanding (A: Dec. 2022 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2021 ) + Accounts Receivable (A: Dec. 2022 )) / count ) / Revenue (A: Dec. 2022 )*Days in Period
=( (0.001 + 0.001) / 2 ) / 0.015*365
=0.001 / 0.015*365
=24.33

Navidea Biopharmaceuticals's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

Days Sales Outstanding (Q: Sep. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Jun. 2023 ) + Accounts Receivable (A: Sep. 2023 )) / count ) / Revenue (A: Sep. 2023 )*Days in Period
=( (0.045 + 0.031) / 2 ) / 0*365 / 4
=0.038 / 0*365 / 4
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Navidea Biopharmaceuticals  (OTCPK:NAVB) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Navidea Biopharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Navidea Biopharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Navidea Biopharmaceuticals Inc (OTCPK:NAVB) » Definitions » Days Sales Outstanding
Comparable Companies
KRBP CMND CYTO PXMD ARDS TSOI ONCO SNPX WINT KTRA OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
N/A
Address
4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Website
https://www.navidea.com
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
Executives
Craig Dais officer: Chief Financial Officer 4995 BRADENTON AVENUE, SUITE 240, DUBLILN OH 43017
Dana J Moss director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jill Stefanelli director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Josh M Wilson director 4795 BRADENTON AVE, STE 240, DUBLIN OH 43017
Scott John K Jr. director, 10 percent owner 30 BLUE HERON DR., GREENWOOD VILLAGE CO 80121
Agnieszka Winkler director C/O INTER-TEL, INCORPORATED, 1615 SOUTH 52ND STREET, TEMPE AZ 85281
Thomas F Farb director C/O SUMMIT PARTNERS, 222 BERKELEY ST 18TH FL, BOSTON MA 02116
Michel Mikhail officer: Chief Regulatory Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Malcolm G Witter director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Alexander L Cappello director C/O THE CHEESECAKE FACTORY INC, 26901 MALIBU HILLS ROAD, CALABASAS HILLS CA 91301
Amit Bhalla director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Joel H. Kaufman officer: Chief Business Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jed Latkin officer: Interim COO 152 W. 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Sarah Kathryn Rouan director 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552